MCID: EST002
MIFTS: 42

Estrogen-Receptor Negative Breast Cancer malady

Categories: Cancer diseases

Aliases & Classifications for Estrogen-Receptor Negative Breast Cancer

Aliases & Descriptions for Estrogen-Receptor Negative Breast Cancer:

Name: Estrogen-Receptor Negative Breast Cancer 12 14

Classifications:



External Ids:

Disease Ontology 12 DOID:0060076

Summaries for Estrogen-Receptor Negative Breast Cancer

MalaCards based summary : Estrogen-Receptor Negative Breast Cancer is related to estrogen-receptor positive breast cancer and breast cancer. An important gene associated with Estrogen-Receptor Negative Breast Cancer is ESR1 (Estrogen Receptor 1), and among its related pathways/superpathways are Glioma and Transcription Androgen Receptor nuclear signaling. The drugs Letrozole and Zoledronic acid have been mentioned in the context of this disorder. Affiliated tissues include breast, lymph node and colon, and related phenotypes are endocrine/exocrine gland and growth/size/body region

Related Diseases for Estrogen-Receptor Negative Breast Cancer

Diseases in the Estrogen-Receptor Positive Breast Cancer family:

Estrogen-Receptor Negative Breast Cancer

Diseases related to Estrogen-Receptor Negative Breast Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 98)
id Related Disease Score Top Affiliating Genes
1 estrogen-receptor positive breast cancer 30.5 ERBB2 ESR1 PGR
2 breast cancer 11.0
3 mouth disease 10.3 ERBB2 PGR
4 bartholin's gland benign neoplasm 10.3 ESR1 PGR
5 cardiovascular organ benign neoplasm 10.3 ESR1 PGR
6 appendix leiomyoma 10.3 ESR1 PGR
7 bronchus adenoma 10.3 ESR1 PGR
8 ovarian benign neoplasm 10.3 ESR1 PGR
9 plexiform neurofibroma 10.3 ESR1 PGR
10 paranasal sinus disease 10.3 ESR1 PGR
11 achondrogenesis 10.3 EGF ERBB2
12 hereditary breast ovarian cancer 10.3 ERBB2 ESR1
13 deafness, autosomal recessive 21 10.3 ESR1 PGR
14 mucoepidermoid thyroid carcinoma 10.3 ERBB2 PGR
15 triple-receptor negative breast cancer 10.3 ERBB2 PGR
16 skin sarcoma 10.3 ERBB2 PGR
17 atypical lipomatous tumor 10.3 ESR1 PGR
18 pediatric intraocular retinoblastoma 10.3 ESR1 PGR
19 congenital disorder of glycosylation, type ic 10.3 ESR1 PGR
20 intestinal perforation 10.3 ESR1 PGR
21 benign fibrous mesothelioma 10.3 EGF ESR1
22 perlman syndrome 10.3 ESR1 PGR
23 x-linked leigh syndrome 10.3 AR ESR1
24 ulceroglandular tularemia 10.3 AR ESR1
25 bladder adenocarcinoma 10.2 ESR1 PGR
26 glioma 10.2 ERBB2 ESR1 PGR
27 cervical lymphoepithelioma-like carcinoma 10.2 ERBB2 ESR1 PGR
28 histiocytic and dendritic cell cancer 10.2 ERBB2 ESR1 PGR
29 her2-receptor negative breast cancer 10.2 ERBB2 ESR1 PGR
30 central nervous system mature teratoma 10.2 ERBB2 ESR1 PGR
31 rectal neoplasm 10.2 ERBB2 ESR1 PGR
32 postpartum depression 10.2 ERBB2 ESR1 PGR
33 combined t cell and b cell immunodeficiency 10.2 ERBB2 ESR1 PGR
34 male reproductive organ benign neoplasm 10.2 ERBB2 ESR1 PGR
35 anal neuroendocrine tumor 10.2 AR ESR1 PGR
36 central nervous system primitive neuroectodermal neoplasm 10.2 ERBB2 ESR1 PGR
37 osteogenesis imperfecta 10.2 AR ESR1 PGR
38 polyembryoma of the ovary 10.2 ERBB2 ESR1 PGR
39 middle ear adenocarcinoma 10.2 AR ESR1 PGR
40 arthus reaction 10.2 ERBB2 ESR1 PGR
41 fallopian tube carcinosarcoma 10.2 ERBB2 ESR1 PGR
42 anus adenocarcinoma 10.2 ERBB2 ESR1 PGR
43 sclerosing hemangioma 10.2 ERBB2 ESR1 PGR
44 t-cell adult acute lymphocytic leukemia 10.2 ERBB2 ESR1 PGR
45 retinal disease 10.2 ERBB2 ESR1 PGR
46 organ system benign neoplasm 10.2 ERBB2 ESR1 PGR
47 his bundle tachycardia 10.2 ERBB2 ESR1 PGR
48 intestinal neuroendocrine benign tumor 10.2 ERBB2 PGR
49 breast duct papilloma 10.2 ERBB2 ESR1 PGR
50 carbuncle 10.2 AR CXCL8 ESR1

Graphical network of the top 20 diseases related to Estrogen-Receptor Negative Breast Cancer:



Diseases related to Estrogen-Receptor Negative Breast Cancer

Symptoms & Phenotypes for Estrogen-Receptor Negative Breast Cancer

MGI Mouse Phenotypes related to Estrogen-Receptor Negative Breast Cancer:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.97 AR EGF ERBB2 ESR1 ETS1 FOXA1
2 growth/size/body region MP:0005378 9.97 AR CCAR2 EGF ERBB2 ESR1 ETS1
3 homeostasis/metabolism MP:0005376 9.91 AR CCAR2 ERBB2 ESR1 ETS1 FOXA1
4 digestive/alimentary MP:0005381 9.88 AR EGF ERBB2 ESR1 FOXA1 WNT5A
5 immune system MP:0005387 9.76 AR CCAR2 EGF ESR1 ETS1 FOXA1
6 integument MP:0010771 9.5 EGF ERBB2 ESR1 ETS1 FOXA1 PGR
7 neoplasm MP:0002006 9.1 AR CCAR2 ERBB2 ESR1 FOXA1 PGR

Drugs & Therapeutics for Estrogen-Receptor Negative Breast Cancer

Drugs for Estrogen-Receptor Negative Breast Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 350)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 112809-51-5 3902
2
Zoledronic acid Approved Phase 4,Phase 3 118072-93-8 68740
3
Anastrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 120511-73-1 2187
4
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
5
Epirubicin Approved Phase 4,Phase 3,Phase 2,Phase 1 56420-45-2 41867
6
Tamoxifen Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 10540-29-1 2733526
7
Exemestane Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 107868-30-4 60198
8
Carboplatin Approved Phase 4,Phase 2,Phase 3,Phase 1 41575-94-4 10339178 498142 38904
9
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
10
Fluorouracil Approved Phase 4,Phase 3,Phase 2 51-21-8 3385
11
Lenograstim Approved Phase 4,Phase 3,Phase 2 135968-09-1
12
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 33069-62-4 36314
13
Pertuzumab Approved Phase 4,Phase 2,Phase 1 145040-37-5, 380610-27-5 2540
14
Trastuzumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 180288-69-1 9903
15
Pamidronate Approved Phase 4 40391-99-9 4674
16
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2 50-02-2 5743
17
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 124-94-7 31307
18
Toremifene Approved, Investigational Phase 4,Phase 3 89778-26-7 3005573
19
Aprepitant Approved, Investigational Phase 4 170729-80-3 151165 6918365
20
Fosaprepitant Approved Phase 4 172673-20-0 219090
21
Ondansetron Approved Phase 4 99614-02-5 4595
22
Docetaxel Approved May 1996, Investigational Phase 4,Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
23
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1 31703
24
Substance P Investigational Phase 4 33507-63-0 44359816
25 Aromatase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
26 Estrogen Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
27 Estrogens Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
28 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
29 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
30 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
31 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
32 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
33 Diphosphonates Phase 4,Phase 3
34 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
35 Estrogen Receptor Modulators Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
36 Selective Estrogen Receptor Modulators Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
37 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1
38 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
39 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
40 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1
41 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1
42 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
43 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
44 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
45 Antiemetics Phase 4,Phase 2
46 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
47 Autonomic Agents Phase 4,Phase 2
48 Dermatologic Agents Phase 4,Phase 3,Phase 2
49 Gastrointestinal Agents Phase 4,Phase 3,Phase 2
50 glucocorticoids Phase 4,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 671)
id Name Status NCT ID Phase
1 Benefits of Breast MRI for Predicting of Histopathologic Cell Type of Small Breast Cancer Unknown status NCT01597999 Phase 4
2 National Screening in Denmark With MR Versus Mammography and Ultrasound of Women With BRCA1 or BRCA2 Mutations Unknown status NCT00413491 Phase 4
3 Clinical Outcomes After Letrozole Treatment According to the Estrogen Receptor Expression in Postmenopausal Women Unknown status NCT01069211 Phase 4
4 Open Label Study of Postmenopausal Women With ER and /or PgR Positive Breast Cancer Treated With Letrozole Completed NCT00237224 Phase 4
5 The ODYSSEY TRIAL Phase IV Trial Evaluating the Palliative Benefit of Pamidronate or Zoledronic Acid in Breast Cancer Completed NCT01907880 Phase 4
6 Treatment of Locally Advanced Breast Cancer With Letrozole in Postmenopausal Women Completed NCT00237133 Phase 4
7 Efficacy and Safety of Letrozole vs. Letrozole Plus Zoledronic Acid as Endocrine Therapy Before Surgery in Postmenopausal Patients With Breast Cancer Completed NCT00375752 Phase 4
8 Adjuvant Endocrine Therapy for Estrogen Receptor-beta Positive Triple Negative Breast Cancer Recruiting NCT02089854 Phase 4
9 Epirubicin Versus Docetaxel Plus Cyclophosphamide in Lymph Node Negative, ER-positive, Her2-negative Breast Cancer Recruiting NCT02549677 Phase 4
10 Evaluation of Tamoxifen's Efficacy for ER/PR Negative,ER-beta Positive Operable Breast Cancer Patients Recruiting NCT02062489 Phase 4
11 Aromasin® Non-Interventional Study Of Early Invasive Breast Cancer Patients In China Recruiting NCT01176916 Phase 4
12 Prevention of Chemotherapy Induced Nausea and Vomiting in Breast Cancer Patients. Active, not recruiting NCT01913990 Phase 4
13 MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I Active, not recruiting NCT01501487 Phase 4
14 Trastuzumab or Lapatinib Ditosylate in Treating Women With Early Breast Cancer Unknown status NCT01104571 Phase 3
15 Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Nonmetastatic Breast Cancer Unknown status NCT01093235 Phase 3
16 Combination Chemotherapy in Treating Women With Breast Cancer Who Have Undergone Surgery Unknown status NCT00039546 Phase 3
17 Fulvestrant With or Without Anastrozole or Exemestane Alone in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer Unknown status NCT00253422 Phase 3
18 Chemotherapy and/or Hormone Therapy With or Without Zoledronate in Treating Women With Stage II or Stage III Breast Cancer Unknown status NCT00072020 Phase 3
19 Premenopausal Patient With Hormone Responsive, HER2 Negative, Lymph Node Positive Breast Cancer Unknown status NCT01622361 Phase 3
20 Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) Completed NCT01881230 Phase 2, Phase 3
21 A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer Completed NCT00938652 Phase 3
22 Low-dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-negative Early Breast Cancer Completed NCT00022516 Phase 3
23 Diagnostic Accuracy and Safety Study of FES PET/CT in Assessment of ER Status of Recurrent or Metastatic Breast Cancer Completed NCT01986569 Phase 3
24 S0230 Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer Completed NCT00068601 Phase 3
25 Combination Chemotherapy With or Without Capecitabine and/or Trastuzumab Before Surgery in Treating Women With Stage I, Stage II, or Stage III Breast Cancer Completed NCT00288002 Phase 3
26 Goserelin in Preventing Early Menopause in Premenopausal Women Undergoing Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer Completed NCT00427245 Phase 3
27 Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Advanced Breast Cancer Women Completed NCT01300351 Phase 3
28 Letrozole or Tamoxifen Citrate in Treating Older Postmenopausal Women Undergoing Surgery for Breast Cancer Completed NCT00949598 Phase 3
29 Prevalence of Genetic Polymorphisms in Genes Coding for Tamoxifen Metabolising Enzymes Completed NCT00966043 Phase 3
30 Optimal Duration of Pre-operative Treatment With Letrozole and to Correlate Clinical Efficacy With Appropriate Surrogate Markers Completed NCT00535418 Phase 2, Phase 3
31 PROACT - Pre-Operative Arimidex Compared To Tamoxifen Completed NCT00232661 Phase 3
32 Study of Faslodex With or Without Concomitant Arimidex Versus Exemestane Following Progression on Non-steroidal Aromatase Inhibitors (NSAI) Completed NCT00944918 Phase 3
33 Primary Chemotherapy With Adriamycin/Cyclophosphamide(AC) vs Taxotere/Xeloda(TX) for Stage II and III Breast Cancer Completed NCT00352378 Phase 3
34 A Study to Evaluate the Efficacy and Safety of Herceptin® (Trastuzumab) in Combination With Arimidex® (Anastrozole) an Aromatase Inhibitor Compared to Arimidex® Alone in Patients With Metastatic Breast Cancer Completed NCT00022672 Phase 3
35 Neo-Adjuvant Chemotherapy (TAC) With or Without Zoledronic Acid in Treating HER2-negative Breast Cancer Patients Completed NCT01099436 Phase 3
36 Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer Completed NCT00567554 Phase 3
37 Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole Completed NCT00863655 Phase 3
38 Arimidex/Tamoxifen Neo Adjuvant Study in Premenopausal Patients With Breast Cancer Under Anti Hormonal Treatment Completed NCT00605267 Phase 3
39 Octreotide, Tamoxifen, and Chemotherapy in Treating Women With Breast Cancer Completed NCT00002967 Phase 3
40 Sequential vs Upfront Intensified Neoadjuvant Chemotherapy in Patients With Large Resectable or Locally Advanced Breast Cancer. Completed NCT00314977 Phase 3
41 4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Completed NCT01626222 Phase 3
42 Phase III Comparison of Adjuvant Chemotherapy W/High-Dose Cyclophosphamide Plus Doxorubicin (AC) vs Sequential Doxorubicin Fol by Cyclophosphamide (A-C) in High Risk Breast Cancer Patients With 0-3 Positive Nodes (Intergroup, CALGB 9394) Completed NCT00590785 Phase 3
43 Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane Completed NCT00036270 Phase 3
44 Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer Completed NCT00026286 Phase 3
45 Randomized Study Comparing CMF and Goserelin + Tamoxifen in Premenopausal Receptor-Positive Patients Completed NCT00309478 Phase 3
46 Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line Treatment in Postmenopausal Patients With Advanced or Metastatic Breast Cancer Completed NCT00545077 Phase 3
47 Cognition in the Study of Tamoxifen and Raloxifene Completed NCT00687102 Phase 3
48 Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy Recruiting NCT01805271 Phase 3
49 Neoadjuvant Endocrine Therapy Versus Chemotherapy in Premenopausal Patients With ER+ & HER2- Breast Cancer Recruiting NCT02535221 Phase 3
50 MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer Recruiting NCT01805076 Phase 3

Search NIH Clinical Center for Estrogen-Receptor Negative Breast Cancer

Genetic Tests for Estrogen-Receptor Negative Breast Cancer

Anatomical Context for Estrogen-Receptor Negative Breast Cancer

MalaCards organs/tissues related to Estrogen-Receptor Negative Breast Cancer:

39
Breast, Lymph Node, Colon, Lung, Endothelial, Bone, Prostate

Publications for Estrogen-Receptor Negative Breast Cancer

Articles related to Estrogen-Receptor Negative Breast Cancer:

(show top 50) (show all 171)
id Title Authors Year
1
Jim Crow and estrogen-receptor-negative breast cancer: US-born black and white non-Hispanic women, 1992-2012. ( 27988896 )
2017
2
Overexpression of lipid metabolism genes and PBX1 in the contralateral breasts of women with estrogen receptor-negative breast cancer. ( 28263391 )
2017
3
Plasma fluorescent oxidation products and risk of estrogen receptor-negative breast cancer in the Nurses' Health Study and Nurses' Health Study II. ( 27294610 )
2016
4
Impact of suppression of tumorigenicity 14 (ST14)/serine protease 14 (prss14) expression analysis on the prognosis and management of estrogen receptor negative breast cancer. ( 27167193 )
2016
5
Estrogen stimulated migration and invasion of estrogen receptor-negative breast cancer cells involves an ezrin-dependent crosstalk between G protein-coupled receptor 30 and estrogen receptor beta signaling. ( 26850467 )
2016
6
Benefit of adjuvant radiotherapy after breast-conserving therapy among elderly women with T1-T2N0 estrogen receptor-negative breast cancer. ( 27328114 )
2016
7
Is estrogen receptor negative breast cancer risk associated with a fast life history strategy? ( 26781544 )
2016
8
Genome-wide Association Studies in Women of African Ancestry Identified 3q26.21 as a Novel Susceptibility Locus for Estrogen Receptor Negative Breast Cancer. ( 27594435 )
2016
9
Adjuvant Radiation Improves Survival in Older Women Following Breast-Conserving Surgery for Estrogen Receptor-Negative Breast Cancer. ( 27431462 )
2016
10
Prognostic significance of Claudin 12 in estrogen receptor-negative breast cancer. ( 26926102 )
2016
11
Life history theory and breast cancer risk: methodological and theoretical challenges: Response to "Is estrogen receptor negative breast cancer risk associated with a fast life history strategy?". ( 26874356 )
2016
12
Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo. ( 28039445 )
2016
13
The Circadian Rhythm Gene Arntl2 Is a Metastasis Susceptibility Gene for Estrogen Receptor-Negative Breast Cancer. ( 27656887 )
2016
14
A novel curcumin derivative increases the cytotoxicity of raloxifene in estrogen receptor-negative breast cancer cell lines. ( 26648459 )
2016
15
Different anticancer effects of Saxifragifolin A on estrogen receptor-positive and estrogen receptor-negative breast cancer cells. ( 26220629 )
2015
16
Effective Targeting of Estrogen Receptor-Negative Breast Cancers with the Protein Kinase D Inhibitor CRT0066101. ( 25852060 )
2015
17
NADH-Cytochrome b5 Reductase 3 Promotes Colonization and Metastasis Formation and Is a Prognostic Marker of Disease-Free and Overall Survival in Estrogen Receptor-Negative Breast Cancer. ( 26351264 )
2015
18
Induction of apoptosis and oxidative stress in estrogen receptor-negative breast cancer, MDA-MB231 cells, by ethanolic mango seed extract. ( 25881293 )
2015
19
N1-Guanyl-1,7-Diaminoheptane Sensitizes Estrogen Receptor Negative Breast Cancer Cells to Doxorubicin by Preventing Epithelial-Mesenchymal Transition through Inhibition of Eukaryotic Translation Initiation Factor 5A2 Activation. ( 26279450 )
2015
20
Effect of sodium/iodide symporter (NIS)-mediated radioiodine therapy on estrogen receptor-negative breast cancer. ( 25955347 )
2015
21
Nitric Oxide-Releasing Aspirin Suppresses NF-I_B Signaling in Estrogen Receptor Negative Breast Cancer Cells in Vitro and in Vivo. ( 26184135 )
2015
22
Expression of sarcosine metabolism-related proteins in estrogen receptor negative breast cancer according to the androgen receptor and HER-2 status. ( 26339363 )
2015
23
Important Role of Menarche in Development of Estrogen Receptor-Negative Breast Cancer in African American Women. ( 26085483 )
2015
24
Interleukin-8 upregulates integrin I^3 expression and promotes estrogen receptor-negative breast cancer cell invasion by activating the PI3K/Akt/NF-I_B pathway. ( 25979232 )
2015
25
Beyond immune density: critical role of spatial heterogeneity in estrogen receptor-negative breast cancer. ( 26621491 )
2015
26
Beyond immune density: critical role of spatial heterogeneity in estrogen receptor-negative breast cancer. ( 25720324 )
2015
27
Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy. ( 25849327 )
2015
28
The activation of G protein-coupled receptor 30 (GPR30) inhibits proliferation of estrogen receptor-negative breast cancer cells in vitro and in vivo. ( 25275589 )
2014
29
Metabolic differences in estrogen receptor-negative breast cancer based on androgen receptor status. ( 24850180 )
2014
30
A positive role of DBC1 in PEA3-mediated progression of estrogen receptor-negative breast cancer. ( 25417701 )
2014
31
Expression of Reactive Oxygen Species-Related Proteins according to Androgen and HER-2 Status in Estrogen Receptor-Negative Breast Cancer. ( 25322848 )
2014
32
In Vitro and In Silico Evaluation of NF-I_B Targeted Costunolide Action on Estrogen Receptor-Negative Breast Cancer Cells-A Comparison with Normal Breast Cells. ( 24733523 )
2014
33
Contralateral prophylactic mastectomy provides no survival benefit in young women with estrogen receptor-negative breast cancer. ( 25081341 )
2014
34
A genome-wide "pleiotropy scan" does not identify new susceptibility loci for estrogen receptor negative breast cancer. ( 24523857 )
2014
35
The prevalence of estrogen receptor-negative breast cancer in Ethiopia. ( 25433805 )
2014
36
Associations between estrogen receptor-negative breast cancer and timing of reproductive events differ between African American and European American women. ( 24718280 )
2014
37
Advances in Preventive Therapy for Estrogen-Receptor-Negative Breast Cancer. ( 24829621 )
2014
38
Expression of autophagy-related proteins according to androgen receptor and HER-2 status in estrogen receptor-negative breast cancer. ( 25140630 )
2014
39
Calcitriol restores antiestrogen responsiveness in estrogen receptor negative breast cancer cells: a potential new therapeutic approach. ( 24678876 )
2014
40
Syndecan binding protein (SDCBP) is overexpressed in estrogen receptor negative breast cancers, and is a potential promoter for tumor proliferation. ( 23533663 )
2013
41
17I^-estradiol promotes the invasion and migration of nuclear estrogen receptor-negative breast cancer cells through cross-talk between GPER1 and CXCR1. ( 23907016 )
2013
42
Proteomic profiling of triple-negative breast carcinomas in combination with a three-tier orthogonal technology approach identifies Mage-A4 as potential therapeutic target in estrogen receptor negative breast cancer. ( 23172894 )
2013
43
Metastasis tumor-associated protein 2 enhances metastatic behavior and is associated with poor outcomes in estrogen receptor-negative breast cancer. ( 24077732 )
2013
44
Intake of specific fruits and vegetables in relation to risk of estrogen receptor-negative breast cancer among postmenopausal women. ( 23532538 )
2013
45
Antineoplastic effects of I+-santalol on estrogen receptor-positive and estrogen receptor-negative breast cancer cells through cell cycle arrest at G2/M phase and induction of apoptosis. ( 23451128 )
2013
46
High expression of class III I^-tubulin predicts good response to neoadjuvant taxane and doxorubicin/cyclophosphamide-based chemotherapy in estrogen receptor-negative breast cancer. ( 23218766 )
2013
47
Antiproliferative effect of the Ginkgo biloba extract is associated with the enhancement of cytochrome P450 1B1 expression in estrogen receptor-negative breast cancer cells. ( 24649031 )
2013
48
Does microenvironment contribute to the etiology of estrogen receptor-negative breast cancer? ( 23325583 )
2013
49
Comparative metabolomics of estrogen receptor positive and estrogen receptor negative breast cancer: alterations in glutamine and beta-alanine metabolism. ( 24125731 )
2013
50
Arctigenin, a dietary phytoestrogen, induces apoptosis of estrogen receptor-negative breast cancer cells through the ROS/p38 MAPK pathway and epigenetic regulation. ( 24140706 )
2013

Variations for Estrogen-Receptor Negative Breast Cancer

Expression for Estrogen-Receptor Negative Breast Cancer

Search GEO for disease gene expression data for Estrogen-Receptor Negative Breast Cancer.

Pathways for Estrogen-Receptor Negative Breast Cancer

GO Terms for Estrogen-Receptor Negative Breast Cancer

Cellular components related to Estrogen-Receptor Negative Breast Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 receptor complex GO:0043235 8.8 EGF ERBB2 PTPRA

Biological processes related to Estrogen-Receptor Negative Breast Cancer according to GeneCards Suite gene sharing:

(show all 25)
id Name GO ID Score Top Affiliating Genes
1 regulation of transcription from RNA polymerase II promoter GO:0006357 9.92 AR ERBB2 ESR1 ETS1 FOXA1
2 positive regulation of transcription, DNA-templated GO:0045893 9.8 AR EGF ESR1 ESRRA ETS1 WNT5A
3 positive regulation of transcription from RNA polymerase II promoter GO:0045944 9.8 AR ESR1 ESRRA ETS1 FOXA1 PGR
4 positive regulation of angiogenesis GO:0045766 9.77 CXCL8 ETS1 WNT5A
5 male gonad development GO:0008584 9.76 AR ESR1 WNT5A
6 transcription initiation from RNA polymerase II promoter GO:0006367 9.71 AR ESR1 ESRRA PGR
7 intracellular receptor signaling pathway GO:0030522 9.63 AR ESR1 ESRRA
8 regulation of cell motility GO:2000145 9.62 EGF ERBB2
9 positive regulation of phosphorylation GO:0042327 9.62 AR EGF
10 dopaminergic neuron differentiation GO:0071542 9.61 FOXA1 WNT5A
11 uterus development GO:0060065 9.61 ESR1 WNT5A
12 negative regulation of ERBB signaling pathway GO:1901185 9.59 EGF ERBB2
13 positive regulation of transcription from RNA polymerase III promoter GO:0045945 9.57 AR ERBB2
14 positive regulation of intracellular estrogen receptor signaling pathway GO:0033148 9.56 AR FOXA1
15 vagina development GO:0060068 9.55 ESR1 WNT5A
16 positive regulation of cell-cell adhesion mediated by cadherin GO:2000049 9.51 FOXA1 WNT5A
17 prostate gland epithelium morphogenesis GO:0060740 9.49 AR FOXA1
18 epithelial cell proliferation involved in mammary gland duct elongation GO:0060750 9.48 ESR1 WNT5A
19 response to estradiol GO:0032355 9.46 ESR1 ESRRA ETS1 FOXA1
20 tertiary branching involved in mammary gland duct morphogenesis GO:0060748 9.43 AR PGR
21 lateral sprouting involved in mammary gland duct morphogenesis GO:0060599 9.37 AR WNT5A
22 mammary gland alveolus development GO:0060749 9.13 AR EGF ESR1
23 steroid hormone mediated signaling pathway GO:0043401 8.92 AR ESR1 ESRRA PGR
24 regulation of transcription, DNA-templated GO:0006355 10.18 AR CCAR2 ERBB2 ESR1 ESRRA ETS1
25 transcription, DNA-templated GO:0006351 10.14 AR CCAR2 ERBB2 ESR1 ESRRA ETS1

Molecular functions related to Estrogen-Receptor Negative Breast Cancer according to GeneCards Suite gene sharing:

(show all 11)
id Name GO ID Score Top Affiliating Genes
1 transcription factor activity, sequence-specific DNA binding GO:0003700 9.91 AR ESR1 ESRRA ETS1 FOXA1 PGR
2 enzyme binding GO:0019899 9.8 AR CCAR2 ESR1 PGR
3 RNA polymerase II core promoter proximal region sequence-specific DNA binding GO:0000978 9.8 AR ESR1 ESRRA ETS1 PGR
4 sequence-specific DNA binding GO:0043565 9.8 AR ESR1 ESRRA ETS1 FOXA1 PGR
5 transcription factor binding GO:0008134 9.76 AR ESR1 ETS1 FOXA1
6 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.65 EGF ERBB2 PTPRA
7 ATPase binding GO:0051117 9.61 AR ESR1 PGR
8 steroid hormone receptor activity GO:0003707 9.56 AR ESR1 ESRRA PGR
9 RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding GO:0004879 9.46 AR ESR1 ESRRA PGR
10 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding GO:0001077 9.43 AR ESR1 ESRRA ETS1 FOXA1 PGR
11 steroid binding GO:0005496 8.92 AR ESR1 ESRRA PGR

Sources for Estrogen-Receptor Negative Breast Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....